Literature DB >> 32933781

Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.

Mohammed Eslam1, Jacob George2.   

Abstract

Entities:  

Year:  2020        PMID： 32933781     DOI： 10.1016/j.jhep.2020.07.045

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  8 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity.

Authors:  Gaggini Melania; Vigna Luisella; Di Piazza Salvina; Gori Francesca; Tirelli Amedea Silvia; Bamonti Fabrizia; Maltinti Maristella; Napolitano Filomena; Chatzianagnostou Kyriazoula; Cristina Vassalle
Journal:  Eat Weight Disord       Date:  2022-05-09       Impact factor: 3.008

3.  Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding.

Authors:  Federica Cioffi; Antonia Giacco; Giuseppe Petito; Rita de Matteis; Rosalba Senese; Assunta Lombardi; Pieter de Lange; Maria Moreno; Fernando Goglia; Antonia Lanni; Elena Silvestri
Journal:  Genes (Basel)       Date:  2022-02-08       Impact factor: 4.096

4.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Authors:  Gabriel Tayguara Silveira Guerreiro; Larisse Longo; Mariana Alves Fonseca; Valessa Emanoele Gabriel de Souza; Mário Reis Álvares-da-Silva
Journal:  Hepatol Int       Date:  2021-03-10       Impact factor: 6.047

Review 5.  Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH.

Authors:  Leigh Goedeke; Gerald I Shulman
Journal:  Mol Metab       Date:  2021-02-03       Impact factor: 7.422

Review 6.  Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Hans-Michael Steffen; Philipp Kasper; Anna Martin; Sonja Lang; Tobias Goeser; Münevver Demir
Journal:  Curr Atheroscler Rep       Date:  2022-05-04       Impact factor: 5.967

7.  Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES).

Authors:  A Lum Han
Journal:  Inflammopharmacology       Date:  2021-07-16       Impact factor: 4.473

8.  Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).

Authors:  Nahum Méndez-Sánchez; Luis Enrique Díaz-Orozco
Journal:  Med Sci Monit       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.